Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2020 | MPNs as a disease spectrum: are genomics the key to one’s destiny?

Raajit Rampal • 27 Aug 2020
Texas MPN Workshop 2020
Myeloproliferative Neoplasms

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives his thoughts on classifying myeloproliferative neoplasms (MPNs) into further sub-divisions, the role of genomics and where we go from here. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raajit Rampal

Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 24 Nov 2022
1:00
How genomic testing has influenced treatment approaches and clinical trial design in MPNs
Raajit Rampal • 26 Aug 2022
1:05
Venetoclax-based combinations in patients with accelerated and blast-phase MPNs
Raajit Rampal • 26 Aug 2022
0:46
The prognostic impact of TP53 mutation in MPNs
Raajit Rampal • 26 Aug 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals